The opposite results were obtained when EGFR kinase activity was inhibited with gefitinib (Figs 4i–m and 5g–k), supporting EGFR modulation as an important “switch” in determining tumor outcomes in a manner dependent on both time of intervention and the underlying disease state. Here, EGFR is linked to neoplasm.